MedTrace Logo

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

NCT05838560 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-21

No results posted yet for this study

Summary

This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.

Conditions

Interventions

DRUG

Dasatinib

dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.

DRUG

quercetin

The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.

Sponsors & Collaborators

  • UConn Health

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Eric Lenze, MD · Washington University School of Medicine, Department of Psychiatry

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2027-10-01
Completion
2027-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05838560 on ClinicalTrials.gov